Verastem Inc (NASDAQ:VSTM) has been assigned an average rating of “Buy” from the ten research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and seven have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $10.64.
A number of equities analysts recently weighed in on VSTM shares. Cann restated a “buy” rating and issued a $6.00 price objective on shares of Verastem in a report on Tuesday, November 7th. Cantor Fitzgerald set a $17.00 price objective on shares of Verastem and gave the stock a “buy” rating in a report on Tuesday, October 31st. Oppenheimer restated a “buy” rating and issued a $6.00 price objective on shares of Verastem in a report on Thursday, October 12th. HC Wainwright set a $10.00 price objective on shares of Verastem and gave the stock a “buy” rating in a report on Wednesday, December 13th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Verastem in a research note on Monday, December 11th.
In related news, Director Timothy J. Barberich bought 60,538 shares of the firm’s stock in a transaction on Tuesday, December 5th. The stock was acquired at an average cost of $3.95 per share, for a total transaction of $239,125.10. Following the purchase, the director now owns 130,000 shares in the company, valued at $513,500. The acquisition was disclosed in a filing with the SEC, which is available through this link. 6.51% of the stock is currently owned by insiders.
Verastem (NASDAQ VSTM) opened at $3.05 on Tuesday. Verastem has a 1-year low of $1.11 and a 1-year high of $5.71. The firm has a market cap of $131.14, a P/E ratio of -1.86 and a beta of 2.19. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.12 and a quick ratio of 3.12.
Verastem (NASDAQ:VSTM) last announced its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported ($0.61) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.29). analysts anticipate that Verastem will post -1.74 earnings per share for the current year.
Verastem Company Profile
Verastem, Inc is a biopharmaceutical company. The Company is focused on discovering and developing drugs to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s advanced product candidates are VS 6063, VS 4718 and VS 5584.
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.